<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of focal or diffuse lupus nephritis resistant to initial therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of focal or diffuse lupus nephritis resistant to initial therapy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of focal or diffuse lupus nephritis resistant to initial therapy</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Our approach to the management of patients with resistant class III or IV (with or without class V) lupus nephritis is largely based upon limited observational data, indirect evidence from clinical trials of patients without resistant disease, and the clinical experience and expert opinion of the authors and editors of the associated UpToDate topic. There is no high-quality evidence to support this approach. Refer to the UpToDate topic on the treatment of focal or diffuse lupus nephritis resistant to initial therapy for more details.</div><div class="graphic_footnotes">CNI: calcineurin inhibitor.<br/>
* This algorithm does not apply to patients with pure class V lupus nephritis. Among patients with focal or diffuse lupus nephritis, resistant disease refers to the failure of initial immunosuppressive therapy to achieve either a complete or partial clinical response. Development of a complete response usually requires a minimum of 6 months and, in some patients, as long as 12 months or more after the initiation of initial therapy. Assessment of the patient's response should begin as early as 3 to 4 months after initial therapy to determine whether the patient is demonstrating a clinical response to therapy (ie, a reduction in proteinuria, improvement or stabilization of the serum creatinine, improvement of the urinary sediment).<br/>
¶ Many cases of suspected treatment resistance are related to nonadherence rather than actual resistance to immunosuppressive therapy. Refer to UpToDate content on the assessment of patient adherence to therapy in patients with focal or diffuse lupus nephritis suspected of being resistant to initial therapy.<br/>
Δ If nonadherence to therapy is likely contributing to the patient's lack of clinical response, we try to understand reasons for nonadherence and tailor our approach to the individual patient. Such patients are not considered to be resistant to therapy. If nonadherence is due to side effects (such as nausea or diarrhea), we would switch to an alternative therapy. If the patient has difficulty remembering to take their medications, we may suggest using a pill box/organizer, setting alarms on their smart phone, or switching to an injectable medication.<br/>
◊ A mycophenolate-based regimen refers to the use of mycophenolate alone or in combination with a CNI (voclosporin, tacrolimus, or cyclosporine) or belimumab. A cyclophosphamide-based regimen refers to the use of cyclophosphamide alone or in combination with belimumab. Glucocorticoids are generally given together with a mycophenolate- or cyclophosphamide-based regimen.<br/>
§ If the patient is already taking mycophenolate in combination with a CNI, belimumab, or rituximab, it is reasonable to switch to a different combination. As an example, if the patient is taking mycophenolate plus a CNI, they may be switched to mycophenolate plus rituximab.<br/>
¥ A rituximab-based regimen refers to the use of rituximab in combination with a CNI (voclosporin, tacrolimus, or cyclosporine), mycophenolate, or cyclophosphamide.</div><div id="graphicVersion">Graphic 134592 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
